Joint venture promises early stage, non-invasive screening for the early diagnosis of lung cancer.
Alpha Szenszor, a leading provider of carbon nanotube (CNT) based sensors, and the Technion-Israel Institute of Technology have announced a joint venture for the commercialization of advanced lung cancer diagnostics based on Volatile Organic Compound (VOC) detection from human breath. They hope their combined expertise will lead to commercializing an economically viable, non-invasive, digital tool for the early diagnosis of lung cancer. “At Alpha Szenszor, we are excited to be working with one of the world’s premier research institutes in a field where the transformational benefits to human life have been so clearly demonstrated,” says Alpha Szenszor CEO Steve Lerner. “We look forward to this partnership with Technion as a critical step in the validation of early stage diagnostics through direct digital detection of gaseous biomarkers.” Alpha Szenszor is a provider of advanced e-nose technology for a wide range of life science applications. “At Technion, we are excited by this new venture with Alpha Szenszor. The combination of strengths and expertise of both parties will greatly enhance our ability to save human lives,” says lead researcher Prof. Hossam Haick, of the Technion Department of Chemical Engineering. “The Technion’s and Alpha Szenszor’s strong IP portfolio and experience will enable the fast and effective transition of this valuable technology from the lab to the medical world where it will be of real benefit in the fight against cancer.”